医学
亚急性皮肤红斑狼疮
药疹
海绵状
皮肤病科
中毒性表皮坏死松解
迟发性皮肤卟啉症
阿维A
疤痕性秃发
脓疱性银屑病
皮肤活检
中止
红斑狼疮
病理
辛伐他汀
异维甲酸
活检
结缔组织病
外科
银屑病
头皮
自身免疫性疾病
药品
内科学
疾病
精神科
抗体
免疫学
作者
Amy E. Adams,Arthur M. Bobrove,Anita C. Gilliam
标识
DOI:10.2310/7750.2010.09042
摘要
Background: The statin medications for lowering of blood cholesterol can be associated with cutaneous lichenoid reactions but also a variety of other adverse cutaneous eruptions, including Stevens-Johnson syndrome, toxic epidermolytic necrolysis, porphyria cutanea tarda, linear IgA bullous dermatosis, and reaction patterns (lupus and dermatomyositis-like and pustular). Cutaneous eruptions (“eczema” in the product literature) owing to simvastatin are reported in approximately 1.5% individuals compared with placebo. Objective: To correlate the clinical and microscopic features of an unusual vesiculobullous reaction to simvastatin. Methods: Retrospective analysis of clinical information and skin biopsies. Results: We present the case of a 70-year-old man with chronic vesiculobullous and pustular annular lesions on distal arms, legs, hands, and feet for 2 years. The eruption was recalcitrant to potent topical corticosteroids. Multiple biopsies at different times showed a spongiotic and lichenoid hypersensitivity reaction resembling contact dermatitis, purpuric drug eruption, and pustular folliculitis. The common themes in the histopathology were spongiosis with microvesiculation, focal lichenoid infiltrates, dermal hemorrhage, and chronic superficial inflammatory cell infiltrates with eosinophils. The eruption began when simvastatin was started, improved when it was stopped, recurred with rechallenge, and cleared when simvastatin was discontinued. Conclusions: Acral cutaneous vesiculobullous eruption is an uncommon adverse drug eruption due to simvastatin, one of many different patterns possible. A high level of suspicion for an unexplained cutaneous eruption in an older individual on statins is important to identification of the disorder and discontinuation of the offending medication.
科研通智能强力驱动
Strongly Powered by AbleSci AI